Biomea Fusion, Inc.

NasdaqGS:BMEA Stock Report

Market Cap: US$103.4m

Biomea Fusion Management

Management criteria checks 1/4

Biomea Fusion's CEO is Mick Hitchcock, appointed in Mar 2025, has a tenure of 1.17 years. total yearly compensation is $2.72M, comprised of 17.9% salary and 82.1% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $164.45K. The average tenure of the management team and the board of directors is 5.1 years and 2.3 years respectively.

Key information

Mick Hitchcock

Chief executive officer

US$2.7m

Total compensation

CEO salary percentage17.92%
CEO tenure1.2yrs
CEO ownership0.2%
Management average tenure5.1yrs
Board average tenure2.3yrs

Recent management updates

Recent updates

Seeking Alpha • Oct 07

Biomea Fusion: Surging On Data, Sinking On Funding - I'm On The Sidelines

Summary Biomea Fusion shares spiked on positive 52-week Phase II data for icovamenib in type 2 diabetes, then fell after a $25M fundraising announcement. BMEA's icovamenib showed durable HbA1c reductions in severe insulin-deficient and GLP-1 non-responder subgroups, but broader efficacy remains unproven in larger populations. Despite a strengthened cash position extending into late 2026, significant risks persist, including funding needs for further trials and competition from established GLP-1 therapies. Given the high risk, uncertain broad efficacy, and dilution, I remain on the sidelines, though BMEA could appeal to speculative investors seeking potential outsized returns. Read the full article on Seeking Alpha
Analysis Article • Aug 17

Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Sep 30

We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Jun 10

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Feb 22

We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Nov 07

Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jul 12

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Mar 29

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO Compensation Analysis

How has Mick Hitchcock's remuneration changed compared to Biomea Fusion's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$45m

Dec 31 2025US$3mUS$487k

-US$62m

Sep 30 2025n/an/a

-US$96m

Jun 30 2025n/an/a

-US$112m

Mar 31 2025n/an/a

-US$129m

Dec 31 2024US$241kn/a

-US$138m

Sep 30 2024n/an/a

-US$144m

Jun 30 2024n/an/a

-US$140m

Mar 31 2024n/an/a

-US$127m

Dec 31 2023US$241kn/a

-US$117m

Sep 30 2023n/an/a

-US$108m

Jun 30 2023n/an/a

-US$102m

Mar 31 2023n/an/a

-US$95m

Dec 31 2022US$241kn/a

-US$82m

Sep 30 2022n/an/a

-US$71m

Jun 30 2022n/an/a

-US$61m

Mar 31 2022n/an/a

-US$52m

Dec 31 2021US$400kn/a

-US$42m

Compensation vs Market: Mick's total compensation ($USD2.72M) is above average for companies of similar size in the US market ($USD627.70K).

Compensation vs Earnings: Mick's compensation has increased whilst the company is unprofitable.

CEO

Mick Hitchcock (75 yo)

1.2yrs
Tenure
US$2,716,511
Compensation

Dr. Michael J. M. Hitchcock, Ph D., also known as Mick, is Business Advisor Sarcomatrix Therapeutics, Corp. Dr. Hitchcock serves as Director at Click Bio Inc. He has been a Director at Biomea Fusion, Inc....

Leadership Team

NamePositionTenureCompensationOwnership
Michael J. Hitchcock
Interim CEO & Director1.2yrsUS$2.72m0.16%
$ 164.4k
Ramses Erdtmann
Co-Founder8.8yrsUS$2.21m2.89%
$ 3.0m
Heow Tan
Chief Technology & Quality Officer5.5yrsno datano data
Thorsten Kirschberg
Executive Vice President of Research5.7yrsno datano data
Stephan Morris
Chief Development Officer4.3yrsno datano data
Ravi Upasani
Executive Vice President of Intellectual Property5.1yrsno datano data
Caroline Perez- Dupont
Senior Vice President of Contracts2.3yrsno datano data
5.1yrs
Average Tenure
64yo
Average Age

Experienced Management: BMEA's management team is seasoned and experienced (5.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Michael J. Hitchcock
Interim CEO & Director5.2yrsUS$2.72m0.16%
$ 164.4k
Ramses Erdtmann
Co-Founder8.8yrsUS$2.21m2.89%
$ 3.0m
Eric Aguiar
Independent Lead Director5.4yrsUS$254.27k0.00028%
$ 289.5
Juliana Chan
Member of Scientific Advisory Board1.6yrsno datano data
Elizabeth Faust
Independent Director3.9yrsUS$223.90k0%
$ 0
Sumita Ray
Independent Director4.9yrsUS$236.65k0%
$ 0
Julio Rosenstock
Member of Scientific Advisory Board1.6yrsno datano data
Julianne Averill
Independent Directorless than a yearUS$382.65kno data
Jeremy Pettus
Member of Scientific Advisory Board2.3yrsno datano data
Rohit Kulkarni
Co-Chair of Scientific Advisory Board2.3yrsno datano data
Juan Frias
Co-Chair of Scientific Advisory Boardless than a yearUS$745.01k0.00048%
$ 496.3
Freddy Eliaschewitz
Member of Scientific Advisory Board1.6yrsno datano data
2.3yrs
Average Tenure
61yo
Average Age

Experienced Board: BMEA's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/15 10:02
End of Day Share Price 2026/05/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biomea Fusion, Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Naureen QuibriaCapital One Securities, Inc.
Yigal NochomovitzCitigroup Inc
Jonathan WollebenCitizens JMP Securities, LLC